Medizinische Universität Graz - Research portal
Publications
Search Items: SGLT2 INHIBITORS, . hits: 8
2022
Kolesnik, E; Scherr, D; Rohrer, U; Benedikt, M; Manninger, M; Sourij, H; von, Lewinski, D
SGLT2 Inhibitors and Their Antiarrhythmic Properties.
Int J Mol Sci. 2022; 23(3):
Doi: 10.3390/ijms23031678
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Wicik, Z; Nowak, A; Jarosz-Popek, J; Wolska, M; Eyileten, C; Siller-Matula, JM; von, Lewinski, D; Sourij, H; Filipiak, KJ; Postuła, M
Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis.
Front Pharmacol. 2022; 13: 901340
Doi: 10.3389/fphar.2022.901340
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Zügner, E; Yang, HC; Kotzbeck, P; Boulgaropoulos, B; Sourij, H; Hagvall, S; Elmore, CS; Esterline, R; Moosmang, S; Oscarsson, J; Pieber, TR; Peng, XR; Magnes, C
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Int J Mol Sci. 2022; 23(14):
Doi: 10.3390/ijms23147966
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2021
Gager, GM; Gelbenegger, G; Jilma, B; von, Lewinski, D; Sourij, H; Eyileten, C; Filipiak, K; Postula, M; Siller-Matula, JM
Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis.
Front Cardiovasc Med. 2021; 8: 691907
Doi: 10.3389/fcvm.2021.691907
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Gager, GM; von, Lewinski, D; Sourij, H; Jilma, B; Eyileten, C; Filipiak, K; Hülsmann, M; Kubica, J; Postula, M; Siller-Matula, JM
Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure.
Biomed Pharmacother. 2021; 143:112169
Doi: 10.1016/j.biopha.2021.112169
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Katzmann, JL; Mason, AM; März, W; Kleber, ME; Niessner, A; Blüher, M; Speer, T; Laufs, U
Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.
CLIN PHARMACOL THER. 2021; 11(2):
Doi: 10.1002/cpt.2153
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Rau, M; Thiele, K; Korbinian, Hartmann, NU; Möllmann, J; Wied, S; Böhm, M; Scharnagl, H; März, W; Marx, N; Lehrke, M
Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
Atherosclerosis. 2021; 330: 8-13.
Doi: 10.1016/j.atherosclerosis.2021.06.915
Web of Science
PubMed
FullText
FullText_MUG
2019
Schernthaner, G; Drexel, H; Moshkovich, E; Zilaitiene, B; Martinka, E; Czupryniak, L; Várkonyi, T; Janež, A; Ducena, K; Lalić, K; Tankova, T; Prázný, M; Smirčić Duvnjak, L; Sukhareva, O; Sourij, H
SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.
BMC ENDOCR DISORD. 2019; 19(1): 64-64.
Doi: 10.1186/s12902-019-0387-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG